Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

ALK or ROS1-positive NSCLC × Crizotinib × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 45 Lung Neoplasms 10 Adenocarcinoma 3 Neoplasms 2 Carcinoma, Squamous Cell 2 ALK-positive NSCLC 2 Recurrence 1 Multiple Endocrine Neoplasia Type 2a 1 Lymphoma, Large-Cell, Anaplastic 1 Granuloma, Plasma Cell 1 Carcinoma, Large Cell 1 Carcinoma 1 Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1 Adenocarcinoma of Lung 1 ALK or ROS1-positive NSCLC 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03672643 2024-11-08

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Pfizer

Phase 4 Terminated

41 enrolled 9 charts

ALK or ROS1-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡